Fresenius Kabi, revenue | Number of Estimates | | 11 | 11 |
Fresenius Kabi, revenue | Highest | | 9,075.8 | 9,659.6 |
Fresenius Kabi, revenue | Consensus (Mean) | 8,414.0 | 8,967.3 | 9,519.9 |
Fresenius Kabi, revenue | Median | | 8,971.0 | 9,529.5 |
Fresenius Kabi, revenue | Lowest | | 8,877.5 | 9,321.0 |
Fresenius Kabi, organic revenue growth (in %) | Number of Estimates | | 10 | 10 |
Fresenius Kabi, organic revenue growth (in %) | Highest | | 7.8 | 7.4 |
Fresenius Kabi, organic revenue growth (in %) | Consensus (Mean) | 10.0 | 6.6 | 6.1 |
Fresenius Kabi, organic revenue growth (in %) | Median | | 6.6 | 6.2 |
Fresenius Kabi, organic revenue growth (in %) | Lowest | | 5.5 | 4.4 |
thereof Medtech, revenue | Number of Estimates | | 10 | 10 |
thereof Medtech, revenue | Highest | | 1,717.9 | 1,873.0 |
thereof Medtech, revenue | Consensus (Mean) | 1,568.0 | 1,677.2 | 1,791.8 |
thereof Medtech, revenue | Median | | 1,682.6 | 1,800.4 |
thereof Medtech, revenue | Lowest | | 1,608.9 | 1,657.1 |
thereof Nutrition, revenue | Number of Estimates | | 10 | 10 |
thereof Nutrition, revenue | Highest | | 2,577.3 | 2,762.3 |
thereof Nutrition, revenue | Consensus (Mean) | 2,399.0 | 2,512.8 | 2,685.0 |
thereof Nutrition, revenue | Median | | 2,519.6 | 2,696.1 |
thereof Nutrition, revenue | Lowest | | 2,426.8 | 2,584.6 |
thereof Biopharma, revenue | Number of Estimates | | 10 | 10 |
thereof Biopharma, revenue | Highest | | 886.0 | 1,112.0 |
thereof Biopharma, revenue | Consensus (Mean) | 611.0 | 827.2 | 985.9 |
thereof Biopharma, revenue | Median | | 829.8 | 981.9 |
thereof Biopharma, revenue | Lowest | | 740.4 | 888.5 |
Subtotal Growth Vectors, revenue | Number of Estimates | | 10 | 10 |
Subtotal Growth Vectors, revenue | Highest | | 5,099.8 | 5,604.3 |
Subtotal Growth Vectors, revenue | Consensus (Mean) | 4,578.0 | 5,017.1 | 5,462.7 |
Subtotal Growth Vectors, revenue | Median | | 5,011.6 | 5,456.0 |
Subtotal Growth Vectors, revenue | Lowest | | 4,883.5 | 5,307.9 |
Pharma (IV Drugs & Fluids), revenue | Number of Estimates | | 10 | 10 |
Pharma (IV Drugs & Fluids), revenue | Highest | | 4,095.0 | 4,299.8 |
Pharma (IV Drugs & Fluids), revenue | Consensus (Mean) | 3,835.0 | 3,954.2 | 4,077.2 |
Pharma (IV Drugs & Fluids), revenue | Median | | 3,938.5 | 4,055.8 |
Pharma (IV Drugs & Fluids), revenue | Lowest | | 3,873.4 | 3,965.5 |
Fresenius Kabi, EBIT | Number of Estimates | | 11 | 11 |
Fresenius Kabi, EBIT | Highest | | 1,523.0 | 1,678.0 |
Fresenius Kabi, EBIT | Consensus (Mean) | 1,319.0 | 1,469.2 | 1,616.2 |
Fresenius Kabi, EBIT | Median | | 1,459.7 | 1,607.8 |
Fresenius Kabi, EBIT | Lowest | | 1,393.2 | 1,535.0 |
Fresenius Kabi, EBIT margin | Number of Estimates | | 11 | 11 |
Fresenius Kabi, EBIT margin | Highest | | 17.1 | 17.8 |
Fresenius Kabi, EBIT margin | Consensus (Mean) | 15.7 | 16.4 | 17.0 |
Fresenius Kabi, EBIT margin | Median | | 16.4 | 17.0 |
Fresenius Kabi, EBIT margin | Lowest | | 15.5 | 16.0 |
thereof Growth Vectors, EBIT | Number of Estimates | | 10 | 10 |
thereof Growth Vectors, EBIT | Highest | | 805.0 | 938.0 |
thereof Growth Vectors, EBIT | Consensus (Mean) | 635.0 | 739.3 | 865.5 |
thereof Growth Vectors, EBIT | Median | | 750.9 | 877.6 |
thereof Growth Vectors, EBIT | Lowest | | 574.2 | 696.6 |
thereof Growth Vectors, EBIT margin (in %) | Number of Estimates | | 10 | 10 |
thereof Growth Vectors, EBIT margin (in %) | Highest | | 16.0 | 16.9 |
thereof Growth Vectors, EBIT margin (in %) | Consensus (Mean) | 13.9 | 14.7 | 15.8 |
thereof Growth Vectors, EBIT margin (in %) | Median | | 15.0 | 16.2 |
thereof Growth Vectors, EBIT margin (in %) | Lowest | | 11.8 | 13.1 |
thereof Pharma (IV Drugs & Fluids), EBIT | Number of Estimates | | 10 | 10 |
thereof Pharma (IV Drugs & Fluids), EBIT | Highest | | 853.5 | 879.2 |
thereof Pharma (IV Drugs & Fluids), EBIT | Consensus (Mean) | 771.0 | 796.5 | 822.5 |
thereof Pharma (IV Drugs & Fluids), EBIT | Median | | 791.7 | 821.9 |
thereof Pharma (IV Drugs & Fluids), EBIT | Lowest | | 774.7 | 790.7 |
thereof Pharma (IV Drugs & Fluids), EBIT margin (in %) | Number of Estimates | | 10 | 10 |
thereof Pharma (IV Drugs & Fluids), EBIT margin (in %) | Highest | | 21.0 | 21.0 |
thereof Pharma (IV Drugs & Fluids), EBIT margin (in %) | Consensus (Mean) | 20.1 | 20.1 | 20.2 |
thereof Pharma (IV Drugs & Fluids), EBIT margin (in %) | Median | | 20.1 | 20.2 |
thereof Pharma (IV Drugs & Fluids), EBIT margin (in %) | Lowest | | 19.7 | 19.5 |
thereof Corporate, EBIT | Number of Estimates | | 9 | 9 |
thereof Corporate, EBIT | Highest | | -20.0 | -20.0 |
thereof Corporate, EBIT | Consensus (Mean) | -87.0 | -79.9 | -84.1 |
thereof Corporate, EBIT | Median | | -86.3 | -91.0 |
thereof Corporate, EBIT | Lowest | | -95.7 | -105.3 |
Fresenius Helios, revenue | Number of Estimates | | 11 | 11 |
Fresenius Helios, revenue | Highest | | 13,429.9 | 14,071.6 |
Fresenius Helios, revenue | Consensus (Mean) | 12,739.0 | 13,348.6 | 13,948.7 |
Fresenius Helios, revenue | Median | | 13,388.4 | 14,014.4 |
Fresenius Helios, revenue | Lowest | | 13,169.1 | 13,682.8 |
Fresenius Helios, organic revenue growth (in %) | Number of Estimates | | 10 | 10 |
Fresenius Helios, organic revenue growth (in %) | Highest | | 5.4 | 5.1 |
Fresenius Helios, organic revenue growth (in %) | Consensus (Mean) | 6.0 | 5.0 | 4.5 |
Fresenius Helios, organic revenue growth (in %) | Median | | 5.1 | 4.7 |
Fresenius Helios, organic revenue growth (in %) | Lowest | | 4.1 | 3.5 |
Helios Germany, revenue | Number of Estimates | | 9 | 9 |
Helios Germany, revenue | Highest | | 8,006.8 | 8,367.1 |
Helios Germany, revenue | Consensus (Mean) | 7,662.0 | 7,973.0 | 8,291.6 |
Helios Germany, revenue | Median | | 7,994.5 | 8,287.2 |
Helios Germany, revenue | Lowest | | 7,899.5 | 8,176.0 |
Helios Spain, revenue | Number of Estimates | | 9 | 9 |
Helios Spain, revenue | Highest | | 5,435.4 | 5,758.3 |
Helios Spain, revenue | Consensus (Mean) | 5,077.0 | 5,377.5 | 5,679.6 |
Helios Spain, revenue | Median | | 5,402.7 | 5,704.5 |
Helios Spain, revenue | Lowest | | 5,269.5 | 5,506.8 |
Fresenius Helios, EBIT | Number of Estimates | | 11 | 11 |
Fresenius Helios, EBIT | Highest | | 1,368.9 | 1,486.1 |
Fresenius Helios, EBIT | Consensus (Mean) | 1,288.0 | 1,325.9 | 1,442.9 |
Fresenius Helios, EBIT | Median | | 1,332.0 | 1,462.6 |
Fresenius Helios, EBIT | Lowest | | 1,250.2 | 1,323.3 |
Fresenius Helios, EBIT margin (in %) | Number of Estimates | | 11 | 11 |
Fresenius Helios, EBIT margin (in %) | Highest | | 10.2 | 10.6 |
Fresenius Helios, EBIT margin (in %) | Consensus (Mean) | 10.1 | 9.9 | 10.3 |
Fresenius Helios, EBIT margin (in %) | Median | | 10.0 | 10.5 |
Fresenius Helios, EBIT margin (in %) | Lowest | | 9.3 | 9.4 |
Helios Germany, EBIT | Number of Estimates | | 9 | 9 |
Helios Germany, EBIT | Highest | | 703.5 | 762.0 |
Helios Germany, EBIT | Consensus (Mean) | 660.0 | 654.6 | 719.7 |
Helios Germany, EBIT | Median | | 652.7 | 732.4 |
Helios Germany, EBIT | Lowest | | 595.2 | 628.3 |
Helios Spain, EBIT | Number of Estimates | | 9 | 9 |
Helios Spain, EBIT | Highest | | 704.4 | 758.1 |
Helios Spain, EBIT | Consensus (Mean) | 629.0 | 676.1 | 723.3 |
Helios Spain, EBIT | Median | | 678.1 | 726.1 |
Helios Spain, EBIT | Lowest | | 638.8 | 670.3 |
Helios Corporate, EBIT | Number of Estimates | | 9 | 9 |
Helios Corporate, EBIT | Highest | | 0.0 | 0.0 |
Helios Corporate, EBIT | Consensus (Mean) | -1.0 | -2.7 | -2.7 |
Helios Corporate, EBIT | Median | | -1.0 | -1.1 |
Helios Corporate, EBIT | Lowest | | -15.0 | -15.0 |
Corporate/Other, revenue | Number of Estimates | | 11 | 11 |
Corporate/Other, revenue | Highest | | 449.9 | 410.0 |
Corporate/Other, revenue | Consensus (Mean) | 373.0 | 373.2 | 374.9 |
Corporate/Other, revenue | Median | | 380.0 | 388.0 |
Corporate/Other, revenue | Lowest | | 298.4 | 313.3 |
Corporate/Other, EBIT | Number of Estimates | | 10 | 10 |
Corporate/Other, EBIT | Highest | | -124.6 | -128.4 |
Corporate/Other, EBIT | Consensus (Mean) | -118.0 | -182.2 | -190.6 |
Corporate/Other, EBIT | Median | | -182.5 | -192.7 |
Corporate/Other, EBIT | Lowest | | -225.0 | -257.2 |